Big Pharma Is Back in the Headlines
It looks like some big pharma companies want to get their holiday shopping done early this year. Two transactions with values north of $1 billion were announced in late November, stimulating a sector that’s been relatively quiet the past few months. The first might not come as a surprise since it’s been circling the rumor mill for some time. Novartis AG (NYSE: NVS) announced the acquisition of The Medicines Company (NASDAQ: MDCO) for $9.7 billion, or $85 per share. The deal value is comprised of a 24% premium over MDCO’s November 22, 2019 closing price of $68.55, as well as the company’s outstanding stock options and convertible debt. MDCO is focused on treating... Read More »
Biogen Eyes Two Ophthalmic Biosimilars
Boston-based Biogen Inc. (NASDAQ: BIIB) has announced a “proposed transaction” with Samsung Bioepis Co., Ltd. to secure the exclusive rights to commercialize two new ophthalmology biosimilars, SB11 referencing Lucentis® and SB15 referencing Eylea®, in major markets worldwide, including the United States, Canada, Europe, Japan and Australia. In addition, Biogen will acquire exclusive commercialization rights for Samsung Bioepis’ anti-TNF portfolio, including Benepali (etanercept), Flixabi (infliximab) and Imraldi (adalimumab), in China. Biogen will also acquire an option to extend its existing commercial agreement with Samsung Bioepis for this anti-TNF portfolio in Europe.... Read More »
Danaher Drops Business Segments to Appease Regulators
Danaher Corporation (NYSE: DHR) is selling a number of its business segments and assets to Sartorius AG (FWB: SRT) for $750 million. The sale includes Danaher’s label-free biomolecular charaterization, chromatography hardware and resins, and microcarriers and particle validation standards businesses, which are part of its Life Sciences segment. Danaher is selling this portion of its Life Sciences segment as a step towards obtaining regulatory approval for its pending acquisition of the GE Biopharma business (NYSE: GE). These businesses generated approximately $140 million in combined revenue in 2018. GE Life Sciences announced the sale of its biopharmaceutical business for $21.4... Read More »
GSK Divests Two Travel Vaccines
GlaxoSmithKline plc (NYSE: GSK) announced recently it is selling two travel vaccines to Bavarian Nordic for $334.7 million upfront, plus a potential $1.06 billion in milestone payments. The sale included rabies vaccine Rabipur (tradename Rabavert in the United States) and Encepur, for the prevention of tick-borne encephalitis. GSK obtained the vaccines as part of a 2015 deal with Novartis (NYSE: NVS). GSK divested its oncology business to Novartis for $300 million and gained the vaccines in return. According to the company’s annual report, GSK generated $7.58 billion from its vaccine segment in 2018. Both vaccines will continue to be manufactured primarily at GSK’s Marburg site in... Read More »
Sobi Grows Product Portfolio With 2nd Deal
Swedish Orphan Biovitrum AB (STO: SOBI), an international specialty healthcare company dedicated to rare diseases, announced its acquisition of Dova Pharmaceuticals, Inc. for $867.7 million (65.3x revenue), or 27$ per share. Dova acquires, develops and commercializes drug candidates for diseases such as thrombocytopenia, a condition that leaves an individual with a low blood platelet count. Its primary candidate, Doptelet, is pending approval for the treatment of chemotherapy-induced thrombocytopenia (CIT). A CVR worth $1.50 per share will be granted if Doptelet is approved, totaling a potential $915 million. An indirect subsidiary of Sobi is acquiring Dove to bolster its hematology and... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
